Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US.

ABSTRACT:

Background

People with HIV (PWH) with persistent viremia and adherence challenges to oral antiretroviral therapy (ART) can achieve viral suppression (VS) with long-acting cabotegravir/rilpivirine (LA-CAB/RPV). US guidelines, however, recommend CAB/RPV only in limited situations. We projected the impact of delaying LA-CAB/RPV implementation while awaiting trial data.

Methods

Using a microsimulation model, we considered 2 approaches for PWH with persistent viremia and intermittent care engagement: daily first-line oral ART or LA-CAB/RPV, both with intensive-support-services (ISS) to maximize adherence. We evaluated 4 CAB/RPV implementation scenarios: 1) Current practice (1% on CAB/RPV); 2) hypothetical Immediate/Delayed complete implementation (100% CAB/RPV after 0-4 yr); 3) t

SUBMITTER: Pei PP 

PROVIDER: S-EPMC12415887 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature